Guangzhou Kingmed Diagnostics Hits Day Low Amid Price Pressure at CNY 30.48

Guangzhou Kingmed Diagnostics Group Co., Ltd. experienced a notable decline today, with the stock dropping by 3.27% on February 24, 2026. The stock reached an intraday low of CNY 30.48, reflecting ongoing challenges within the company. Over the past week, the stock has decreased by 1.9%, while its performance over the last month shows a significant decline of 16.85%. Year-to-date, the stock has managed a modest gain of 7.55%, contrasting sharply with its one-year performance, which stands at a loss of 7.58%. The company has faced consistent underperformance against the China Shanghai Composite, particularly over the last three years, where it has recorded a staggering decline of 66.47%. Financial metrics indicate a concerning trend, with net sales for the first half of the year reported at CNY 3,071.65 million, reflecting an 18.69% decrease. Additionally, the net profit for the same period was reported at CNY -51.82 million, marking a significant decline of 146.08%. As a large-cap player in the Pharmaceuticals & Biotechnology sector, Guangzhou Kingmed Diagnostics continues to navigate a challenging market landscape.